Compare Stocks

Enter up to ten stock symbols separated by a comma or space (ex. SGEN,NVZMY,TECH,ARGX,BIIB).

NASDAQ:SGEN OTCMKTS:NVZMY NASDAQ:TECH NASDAQ:ARGX NASDAQ:BIIB

Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
SGEN Seagen	$143.00 -2.4%	$139.18	$105.43 ▼ $192.79	$26.32B	0.85	1.13 million shs	1.10 million shs
NVZMY Novozymes A/S	$60.90 -3.1%	$65.77	$57.85 ▼ $83.31	$13.90B	0.57	18,841 shs	20,436 shs
TECH Bio-Techne	$359.09 -3.2%	$407.05	$335.02 ▼ $543.85	$14.09B	1.24	267,344 shs	241,552 shs
ARGX argenx	$304.71 -3.5%	$307.95	$249.50 ▼ $356.78	$16.34B	1.11	272,656 shs	255,495 shs
BIIB Biogen	$195.71 -3.5%	$207.02	$187.16 ▼ $468.55	$28.66B	0.42	1.29 million shs	1.20 million shs

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
SGEN Seagen	-2.42%	+19.72%	-0.96%	+15.17%	-3.53%
NVZMY Novozymes A/S	-3.09%	+0.15%	-9.19%	+0.73%	-16.92%
TECH Bio-Techne	-3.22%	+6.03%	-12.85%	-9.82%	-10.23%
ARGX argenx	-3.55%	+7.16%	-3.86%	+5.84%	+10.51%
BIIB Biogen	-3.54%	+2.43%	-7.92%	-7.07%	-30.35%

MarketRank™

Company	Overall Score	Analyst's Opinion	Community Rank	Dividend Strength	Company Ownership	Earnings & Valuation
SGEN Seagen	2.31 of 5 Stars	2.4	4.4	0.0	4.2	0.6
NVZMY Novozymes A/S	1.86 of 5 Stars	3.1	3.3	1.7	0.0	1.3
TECH Bio-Techne	2.89 of 5 Stars	3.3	4.3	1.7	3.3	1.9
ARGX argenx	1.70 of 5 Stars	2.5	4.5	0.0	0.8	0.6
BIIB Biogen	2.29 of 5 Stars	4.3	4.9	0.0	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
SGEN Seagen	2.70	Buy	$160.00	11.89% Upside
NVZMY Novozymes A/S	2.13	Hold	$425.00	597.87% Upside
TECH Bio-Techne	2.60	Buy	$504.17	40.40% Upside
ARGX argenx	3.00	Buy	$360.94	18.45% Upside
BIIB Biogen	2.50	Buy	$275.47	40.75% Upside

Current Analyst Ratings

Latest SGEN, NVZMY, TECH, ARGX, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2022	ARGX argenx	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
5/6/2022	ARGX argenx	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	€350.00 ➝ €370.00
5/5/2022	TECH Bio-Techne	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target		$520.00 ➝ $500.00
5/5/2022	TECH Bio-Techne	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target		$600.00 ➝ $500.00
5/4/2022	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target		$240.00 ➝ $225.00
5/4/2022	BIIB Biogen	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target		$219.00 ➝ $210.00
5/3/2022	ARGX argenx	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$375.00
4/29/2022	NVZMY Novozymes A/S	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Reduce ➝ Hold
4/28/2022	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
4/27/2022	NVZMY Novozymes A/S	Nordea Equity Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Hold
4/25/2022	TECH Bio-Techne	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$400.00 ➝ $370.00

(Data available from 5/19/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
SGEN Seagen	$1.57B	16.72	N/A	N/A	$16.76 per share	8.53
NVZMY Novozymes A/S	$2.38B	5.84	$2.22 per share	27.44	$8.51 per share	7.16
TECH Bio-Techne	$931.03M	15.13	$8.02 per share	44.76	$40.40 per share	8.89
ARGX argenx	$539.42M	30.29	N/A	N/A	$49.05 per share	6.21
BIIB Biogen	$10.98B	2.61	$26.70 per share	7.33	$74.61 per share	2.62

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
SGEN Seagen	-$674.47M	-$3.77	N/A	N/A	N/A	-41.32%	-21.86%	-18.07%	8/4/2022 (Estimated)
NVZMY Novozymes A/S	$500.53M	$1.74	35.00	33.10	7.96	21.04%	27.43%	13.88%	N/A
TECH Bio-Techne	$140.41M	$5.48	65.53	43.11	2.01	20.95%	16.82%	12.21%	8/4/2022 (Estimated)
ARGX argenx	-$408.27M	-$11.54	N/A	N/A	N/A	-147.47%	-32.54%	-29.44%	8/4/2022 (Estimated)
BIIB Biogen	$1.56B	$9.77	20.03	11.90	1.24	13.40%	23.46%	10.85%	7/28/2022 (Estimated)

Latest SGEN, NVZMY, TECH, ARGX, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2022	3/31/2022	ARGX argenx	-$5.08	-$4.36	+$0.72	N/A	N/A	N/A
5/4/2022	Q3 2022	TECH Bio-Techne	$1.75	$1.96	+$0.21	$2.44	$279.27 million	$290.40 million
5/3/2022	Q1 2022	BIIB Biogen	$4.41	$3.62	-$0.79	$5.18	$2.50 billion	$2.53 billion
4/28/2022	Q1 2022	SGEN Seagen	-$0.98	-$0.74	+$0.24	-$0.74	$401.75 million	$426.50 million
3/3/2022	Q4 2021	ARGX argenx	-$4.88	-$4.76	+$0.12	-$4.76	$18.87 million	$44.84 million

(Earnings results data provided by Zacks Investment Research)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
SGEN Seagen	N/A	N/A	N/A	N/A	N/A
NVZMY Novozymes A/S	$0.55	0.90%	N/A	31.61%	N/A
TECH Bio-Techne	$1.28	0.36%	N/A	23.36%	N/A
ARGX argenx	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A

Latest SGEN, NVZMY, TECH, ARGX, and BIIB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/5/2022	TECH Bio-Techne	quarterly	$0.32	0.3%	5/13/2022	5/16/2022	5/27/2022
3/15/2022	NVZMY Novozymes A/S		$0.567008	0.95%	3/17/2022	3/18/2022	4/5/2022

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
SGEN Seagen	N/A	5.22	4.70
NVZMY Novozymes A/S	0.30	1.38	0.85
TECH Bio-Techne	0.14	3.56	2.79
ARGX argenx	N/A	8.44	8.08
BIIB Biogen	0.56	2.01	1.70

Ownership

Institutional Ownership

Company	Institutional Ownership
SGEN Seagen	90.37%
NVZMY Novozymes A/S	0.03%
TECH Bio-Techne	94.36%
ARGX argenx	58.76%
BIIB Biogen	83.92%

Insider Ownership

Company	Insider Ownership
SGEN Seagen	27.3%
NVZMY Novozymes A/S	N/A
TECH Bio-Techne	4.1%
ARGX argenx	N/A
BIIB Biogen	0.62%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
SGEN Seagen	2,675	184.08 million	133.82 million	Optionable
NVZMY Novozymes A/S	6,527	228.26 million	N/A	Not Optionable
TECH Bio-Techne	2,600	39.23 million	37.63 million	Optionable
ARGX argenx	650	53.62 million	N/A	Optionable
BIIB Biogen	9,610	146.45 million	145.54 million	Optionable

SGEN, NVZMY, TECH, ARGX, and BIIB Headlines

Source	Headline
	Biogen's Alex Cameron Discusses Biogen-MIT Biotech in Action - CSRwire.com csrwire.com - May 16 at 2:39 PM
	Biogen's Aduhelm can't catch a break even in Alzheimer's trials as neurologists worry about safety, efficacy - FiercePharma fiercepharma.com - May 16 at 2:39 PM
	How Many Biogen Inc. (NASDAQ:BIIB) Shares Do Institutions Own? finance.yahoo.com - May 16 at 2:39 PM
	Multiple Sclerosis Treatment Market Size And Forecast \| Teva Pharmaceutical Industries, Bayer, Biogen Idec, Pfizer, Novartis – Queen Anne and Mangolia News - Queen Anne and Mangolia News magnolianews.net - May 14 at 11:54 PM
	Biogen All but Throws in the Towel on Once-Promising Alzheimer's Drug gurufocus.com - May 12 at 5:09 PM
	Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration - Genetic Engineering & Biotechnology News genengnews.com - May 12 at 3:50 PM
	Chancery Orders Biogen To Give Documents To Investor - Law360 law360.com - May 11 at 6:32 PM
	Eisai, Biogen Take Another Step Toward Potential Approval of Alzheimer's Drug Lecanemab - BioSpace biospace.com - May 11 at 1:32 PM
	EIT Health and Biogen announce winners of first 'neurotechprize' - PMLiVE pmlive.com - May 11 at 8:31 AM
	Biogen pivots to second amyloid-targeted Alzheimer's drug with accelerated approval filing from partner Eisai - Endpoints News endpts.com - May 10 at 8:39 PM
	The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's - Benzinga benzinga.com - May 10 at 10:37 AM
	Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug finance.yahoo.com - May 10 at 10:37 AM
	EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY finance.yahoo.com - May 10 at 12:06 AM
	Chancery Should Order Biogen To Give Up Docs, Report Says - Law360 law360.com - May 9 at 7:05 PM
	ICYMI: Biogen CEO Michel Vounatsos to Step Down After the U.S. Government's Medicare ... - Latest Tweet by - LatestLY latestly.com - May 9 at 8:56 AM
	Biogen's shakeup from the top; How to build a biotech today; David Sabatini backs out of NYU; and more - Endpoints News endpts.com - May 7 at 10:22 AM
	Q3 2022 EPS Estimates for Biogen Inc. Boosted by Analyst (NASDAQ:BIIB) americanbankingnews.com - May 7 at 2:58 AM
	SVB Leerink Analysts Lower Earnings Estimates for Biogen Inc. (NASDAQ:BIIB) americanbankingnews.com - May 7 at 1:54 AM
	Biogen Inc. (NASDAQ:BIIB) to Post Q2 2022 Earnings of $3.86 Per Share, Wedbush Forecasts americanbankingnews.com - May 7 at 1:54 AM
	Q2 2022 Earnings Forecast for Biogen Inc. (NASDAQ:BIIB) Issued By William Blair americanbankingnews.com - May 7 at 1:54 AM
	TAR DNA Binding Protein 43 Market Size & Revenue Analysis \| Biogen Inc, ImStar Therapeutics Inc., Primary Peptides – Queen Anne and Mangolia News - Queen Anne and Mangolia News magnolianews.net - May 6 at 11:40 PM
	Biogen Licensing Deal is Sweet Music for Bolstering MS Portfolio - BioSpace biospace.com - May 6 at 6:40 PM
	Beset by challenges with its Alzheimer’s disease drug, Biogen pivots marketwatch.com - May 6 at 1:39 PM
	StockWatch: Investors Unfazed by Biogen CEO Search, Aduhelm Cutbacks genengnews.com - May 6 at 1:39 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.